A Study Comparing Blood Transfusion Requirement and Frequency of Blood Transfusion In Splenectomized and Non Splenectomized Children with Beta Thalassemia Major - Our Institutional Experience
Keywords:
Thalassemia Major, Splenectomy, Blood transfusionAbstract
Introduction : Beta thalassemia major is an autosomal recessive blood disorder. Thalassemia refers to a group of genetic disorders of globin chain production in which there is an imbalance between the ????-globin and ????-globin chain production. ????-Thalassemia syndromes result from a decrease in ????-globin chains, which results in a relative excess of ????-globin chains. Material and Methods : Sample size : 45. Duration of Study: June 2016- June 2018. Children from 5 to 15 years of age who are diagnosed case of Beta thalassemia Major with blood requirement more than 200 ml/kg/year. The patients were divided into 2
groups: 5 to 10 years and 11 to 15 years. History and complete physical examination with haematological workup were done in all cases. Pre-transfusion
haemoglobin of all 45 patients was noted. The risks and benefits of splenectomy were explained, 20 patients were selected for splenectomy. Result : From the Age group of 5 to 10 years there were Total 22 patients out of which 11 underwent splenectomy. The normal haemoglobin level in the children of this age group is 12.5 gm/dl on an average. The average haemoglobin level in non-splenectomised patients were 7 gm/dl. On the other hand the average
haemoglobin level in a splenectomised patient was 9gm/dl, 6 months after splenectomy. The annual blood requirement of all splenectomised and non - splenectomised patients was compared. In non splenectomised patients the annual requirement was 260 ml/kg/year while in splenectomised patients it was 210 ml/kg/year. Conclusion : The mean haemoglobin levels were on a higher side in splectomized patients as compared to their pre-operative levels as well as compared to non-splenectomized patients. The blood requirement significantly reduced in splenectomized patients to 210 ml/kg/year.
Downloads
References
Weatherall D. J. (2015). "The Thalassemias: Disorders of Globin Synthesis". McGraw Hill Professional. p. 725-28.
Clinton P (October 2008). "Treatment of thalassemia". Pediatr Endocrinol Rev. 6 (Suppl 1): 208–13.
Neufeld, EJ (2010). "Update on iron chelators in thalassemia". Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2010: 451–5.
Nelson Textbook Of Paediatrics (2018) First South Asia Edition.
Cianciulli P (October 2008). "Treatment of iron overload in thalassemia". Pediatr Endocrinol Rev. 6 (Suppl 1): 208–13.
Richard D. Propper, Susan B. Shurin, David G. Nathan. Reassessment of the Use of Desferrioxamine B in Iron Overload. Engl J Med 1976; 294:1421-1423.
Cohen A, Antanio Piga, Maria Cappelini. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ?-thalassemia. Blood 2006 107:3455-3462.
Baty J M, Blackan K D, Diamond LK,. Blood studies in infants and in children. Erythroblastic anaemia, a clinical and pathological study. Amer J Dis Child.43:667.2006.
Published
How to Cite
Issue
Section
Copyright (c) 2018 Dr. Prajakta Ghatage , Dr. Ramesh Kothari , Dr. Sunil Mhaske
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.